- Home
- GANX vs ACHL Comparison
GANX vs ACHL Comparison
Compare GANX & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- ACHL
- Stock Information
- Founded
- GANX 2017
- ACHL 2016
- Country
- GANX United States
- ACHL United Kingdom
- Employees
- GANX N/A
- ACHL N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GANX Health Care
- ACHL Health Care
- Exchange
- GANX Nasdaq
- ACHL Nasdaq
- Market Cap
- GANX 41.9M
- ACHL 40.4M
- IPO Year
- GANX 2021
- ACHL 2021
- Fundamental
- Price
- GANX $1.85
- ACHL $1.05
- Analyst Decision
- GANX Strong Buy
- ACHL Hold
- Analyst Count
- GANX 4
- ACHL 3
- Target Price
- GANX $7.75
- ACHL $2.83
- AVG Volume (30 Days)
- GANX 281.8K
- ACHL 142.6K
- Earning Date
- GANX 11-14-2024
- ACHL 11-14-2024
- Dividend Yield
- GANX N/A
- ACHL N/A
- EPS Growth
- GANX N/A
- ACHL N/A
- EPS
- GANX N/A
- ACHL N/A
- Revenue
- GANX N/A
- ACHL N/A
- Revenue This Year
- GANX N/A
- ACHL N/A
- Revenue Next Year
- GANX $300.03
- ACHL N/A
- P/E Ratio
- GANX N/A
- ACHL N/A
- Revenue Growth
- GANX N/A
- ACHL N/A
- 52 Week Low
- GANX $0.89
- ACHL $0.63
- 52 Week High
- GANX $5.33
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- GANX 39.86
- ACHL 60.22
- Support Level
- GANX $1.64
- ACHL $0.99
- Resistance Level
- GANX $2.34
- ACHL $1.12
- Average True Range (ATR)
- GANX 0.27
- ACHL 0.04
- MACD
- GANX -0.09
- ACHL -0.00
- Stochastic Oscillator
- GANX 19.90
- ACHL 54.84
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.